NASDAQ: NEUPNeuphoria Therapeutics Inc Stock
$7.13+0.11 (+1.57%)
Updated Jul 3, 2025
NEUP Price
$7.13
Fair Value Price
$0.05
Market Cap
$13.40M
52 Week Low
$2.12
52 Week High
$12.55
P/E
N/A
P/B
0.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
N/A
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NEUP Overview
Bionomics Ltd is a clinical-stage biopharmaceutical company focused on drug candidates to transform the lives of patients suffering from serious central nervous system disorders. The company's lead candidate, BNC210, is a treatment for Social Anxiety Disorder and Post-Traumatic Stress Disorder. Bionomics was incorporated in 1996 and is based in Eastwood, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NEUP's potential to beat the market
- NEUP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NEUP
RankedUnranked of 468
RankedUnranked of 468
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.59 | A | |
| $3.58 | A | |
| $46.15 | A |
Be the first to know about important NEUP news, forecast changes, insider trades & much more!
NEUP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NEUP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NEUP ($7.13) is overvalued by 13,246.86% relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NEUP ($7.13) is not significantly undervalued (13,246.86%) relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NEUP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more NEUP due diligence checks available for Premium users.
Valuation
NEUP fair value
Fair Value of NEUP stock based on Discounted Cash Flow (DCF)
Price
$7.13
Fair Value
$0.05
Overvalued by
13,246.86%
NEUP ($7.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NEUP ($7.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NEUP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-154.26x
Market
30.96x
NEUP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
4.54x
NEUP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NEUP's financial health
Profit margin
Revenue
$9.5M
Net Income
$7.1M
Profit Margin
75.1%
Assets to liabilities
Assets
$19.4M
Liabilities
$3.0M
Debt to equity
0.18
NEUP's short-term assets ($11.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NEUP's short-term assets ($11.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NEUP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.2M
Investing
$0.0
Financing
$735.8k
NEUP vs Biotech Stocks
Neuphoria Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.